Keywords: bayer, onyx, sorafenib, enters, fda, program, german
Bayer and Onyx' Sorafenib enters the US FDA's Program 1
Article | 16 May 2005
German drugmaker Bayer and the USA's Onyx Pharmaceuticals say that their co-developed anticancer agent, sorafenib (BAY 43-9006), has been accepted ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
